Ignite Creation Date:
2024-05-06 @ 1:49 PM
Last Modification Date:
2024-10-26 @ 1:20 PM
Study NCT ID:
NCT04133337
Status:
UNKNOWN
Last Update Posted:
2019-10-21
First Post:
2019-10-17
Brief Title:
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
Sponsor:
Sichuan Cancer Hospital and Research Institute
Organization:
Sichuan Cancer Hospital and Research Institute
Study Overview
Official Title:
One-arm Exploratory Study on the Efficacy and Safety of Apatinib Combined With SHR-1210 Injection PD-1 Antibody in the Treatment of Removable IB-IIIA Non-small Cell Lung Cancer
Status:
UNKNOWN
Status Verified Date:
2019-10
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None